Keyword: JP Morgan Healthcare Conference

News

BioMarin Won't Sell Itself for 25-30% Premium

09.01.2013 - BioMarin Pharmaceutical, which makes high-priced drugs used to treat rare diseases, would not consider a buy-out offer for even a 25-30% premium, according to the company's chief...

News

Amgen Trims 2012 EPS Estimate, Citing R&D Tax Credit Delay

09.01.2013 - Amgen, the world's largest biotechnology company, on Tuesday lowered its outlook for 2012 earnings per share by 10 cents, citing a delay in the impact of a U.S. tax credit for...

News

Actelion Sticks to Forecast for Return to Growth from 2014

08.01.2013 - Actelion, Europe's biggest biotech company, is sticking to its forecast for core earnings to return to growth from 2014 as cost cuts and a new heart and lung treatment offset...